Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats

Ludmila Belayev, Larissa Khoutorova, Weizhao Zhao, Alexey Vigdorchik, Andrey Belayev, Raul Busto, Ella Magal, Myron Ginsberg

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background and Purpose - Darbepoetin alfa is a novel erythropoiesis- stimulating protein developed for treating anemia. In animal models, exogenous recombinant human erythropoietin has been reported to be beneficial in treating experimental cerebral ischemia. In this study, we determined whether darbepoetin alfa would protect in a rat model of transient focal cerebral ischemia. Methods - Rats received 2-hour middle cerebral artery suture-occlusion. The drug (darbepoetin alfa, 10 μg/kg) or vehicle was administered intraperitoneally 2 hours after onset of middle cerebral artery occlusion. Animals were allowed to survive for 3 or 14 days. Behavioral tests were performed sequentially. Infarct volumes and brain swelling were determined. Results - Darbepoetin alfa-treated rats showed improved neuroscores relative to vehicle-treated animals beginning within 1 hour of treatment and persisting throughout the 14-day survival period. Darbepoetin alfa significantly reduced corrected total (cortical + subcortical) infarct volume (56.3±20.6 and 110.8±6.8 mm3, respectively) and total infarct areas at multiple levels compared with vehicle in the 14-day survival group. Brain swelling was not affected by treatment. Conclusion - Darbepoetin alfa confers behavioral and histological neuroprotection after focal ischemia in rats.

Original languageEnglish
Pages (from-to)1065-1070
Number of pages6
JournalStroke
Volume36
Issue number5
DOIs
StatePublished - May 1 2005

Fingerprint

Neuroprotective Agents
Brain Ischemia
Recombinant Proteins
Middle Cerebral Artery Infarction
Brain Edema
Survival
Transient Ischemic Attack
Erythropoietin
Darbepoetin alfa
Sutures
Anemia
Ischemia
Animal Models
Pharmaceutical Preparations

Keywords

  • Brain edema
  • Cerebral ischemia
  • Focal
  • Middle cerebral artery occlusion
  • Neuroprotection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. / Belayev, Ludmila; Khoutorova, Larissa; Zhao, Weizhao; Vigdorchik, Alexey; Belayev, Andrey; Busto, Raul; Magal, Ella; Ginsberg, Myron.

In: Stroke, Vol. 36, No. 5, 01.05.2005, p. 1065-1070.

Research output: Contribution to journalArticle

Belayev, Ludmila ; Khoutorova, Larissa ; Zhao, Weizhao ; Vigdorchik, Alexey ; Belayev, Andrey ; Busto, Raul ; Magal, Ella ; Ginsberg, Myron. / Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. In: Stroke. 2005 ; Vol. 36, No. 5. pp. 1065-1070.
@article{81ee1ff072a844afa8efc4413c396c25,
title = "Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats",
abstract = "Background and Purpose - Darbepoetin alfa is a novel erythropoiesis- stimulating protein developed for treating anemia. In animal models, exogenous recombinant human erythropoietin has been reported to be beneficial in treating experimental cerebral ischemia. In this study, we determined whether darbepoetin alfa would protect in a rat model of transient focal cerebral ischemia. Methods - Rats received 2-hour middle cerebral artery suture-occlusion. The drug (darbepoetin alfa, 10 μg/kg) or vehicle was administered intraperitoneally 2 hours after onset of middle cerebral artery occlusion. Animals were allowed to survive for 3 or 14 days. Behavioral tests were performed sequentially. Infarct volumes and brain swelling were determined. Results - Darbepoetin alfa-treated rats showed improved neuroscores relative to vehicle-treated animals beginning within 1 hour of treatment and persisting throughout the 14-day survival period. Darbepoetin alfa significantly reduced corrected total (cortical + subcortical) infarct volume (56.3±20.6 and 110.8±6.8 mm3, respectively) and total infarct areas at multiple levels compared with vehicle in the 14-day survival group. Brain swelling was not affected by treatment. Conclusion - Darbepoetin alfa confers behavioral and histological neuroprotection after focal ischemia in rats.",
keywords = "Brain edema, Cerebral ischemia, Focal, Middle cerebral artery occlusion, Neuroprotection",
author = "Ludmila Belayev and Larissa Khoutorova and Weizhao Zhao and Alexey Vigdorchik and Andrey Belayev and Raul Busto and Ella Magal and Myron Ginsberg",
year = "2005",
month = "5",
day = "1",
doi = "10.1161/01.STR.0000160753.36093.da",
language = "English",
volume = "36",
pages = "1065--1070",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats

AU - Belayev, Ludmila

AU - Khoutorova, Larissa

AU - Zhao, Weizhao

AU - Vigdorchik, Alexey

AU - Belayev, Andrey

AU - Busto, Raul

AU - Magal, Ella

AU - Ginsberg, Myron

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Background and Purpose - Darbepoetin alfa is a novel erythropoiesis- stimulating protein developed for treating anemia. In animal models, exogenous recombinant human erythropoietin has been reported to be beneficial in treating experimental cerebral ischemia. In this study, we determined whether darbepoetin alfa would protect in a rat model of transient focal cerebral ischemia. Methods - Rats received 2-hour middle cerebral artery suture-occlusion. The drug (darbepoetin alfa, 10 μg/kg) or vehicle was administered intraperitoneally 2 hours after onset of middle cerebral artery occlusion. Animals were allowed to survive for 3 or 14 days. Behavioral tests were performed sequentially. Infarct volumes and brain swelling were determined. Results - Darbepoetin alfa-treated rats showed improved neuroscores relative to vehicle-treated animals beginning within 1 hour of treatment and persisting throughout the 14-day survival period. Darbepoetin alfa significantly reduced corrected total (cortical + subcortical) infarct volume (56.3±20.6 and 110.8±6.8 mm3, respectively) and total infarct areas at multiple levels compared with vehicle in the 14-day survival group. Brain swelling was not affected by treatment. Conclusion - Darbepoetin alfa confers behavioral and histological neuroprotection after focal ischemia in rats.

AB - Background and Purpose - Darbepoetin alfa is a novel erythropoiesis- stimulating protein developed for treating anemia. In animal models, exogenous recombinant human erythropoietin has been reported to be beneficial in treating experimental cerebral ischemia. In this study, we determined whether darbepoetin alfa would protect in a rat model of transient focal cerebral ischemia. Methods - Rats received 2-hour middle cerebral artery suture-occlusion. The drug (darbepoetin alfa, 10 μg/kg) or vehicle was administered intraperitoneally 2 hours after onset of middle cerebral artery occlusion. Animals were allowed to survive for 3 or 14 days. Behavioral tests were performed sequentially. Infarct volumes and brain swelling were determined. Results - Darbepoetin alfa-treated rats showed improved neuroscores relative to vehicle-treated animals beginning within 1 hour of treatment and persisting throughout the 14-day survival period. Darbepoetin alfa significantly reduced corrected total (cortical + subcortical) infarct volume (56.3±20.6 and 110.8±6.8 mm3, respectively) and total infarct areas at multiple levels compared with vehicle in the 14-day survival group. Brain swelling was not affected by treatment. Conclusion - Darbepoetin alfa confers behavioral and histological neuroprotection after focal ischemia in rats.

KW - Brain edema

KW - Cerebral ischemia

KW - Focal

KW - Middle cerebral artery occlusion

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=18244372152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244372152&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000160753.36093.da

DO - 10.1161/01.STR.0000160753.36093.da

M3 - Article

VL - 36

SP - 1065

EP - 1070

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 5

ER -